Biotech | April 25, 2022
‘DREAM-ND’ and ‘DREAM-D’ Phase 3 trials of Desidustat published in American Journal of Nephrology
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Desidustat is currently approved only in India as OxemiaTM for patients with CKD induced anemia
Real-world evidence from more than 850,000 hospitalized patients provides clinical insights on the use of Veklury (remdesivir) as stand of care Covid-19 treatment
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
The latest technology from ZEISS empowers surgeons with one complete, digitally integrated cataract workflow for efficiency without compromise
Strive to empower public health with disinfection robotics solutions in post-pandemic era
This product will be manufactured at Lupin’s Nagpur facility in India
The product will be manufactured at Lupin’s facility in Goa, India
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
The expansion positions Cambrex with the largest and most advanced API facility in the United States
Dr. Matthew Weiss presents data on patient organoids & cancer care at the American Surgical Association annual meeting
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
